<DOC>
	<DOCNO>NCT01891227</DOCNO>
	<brief_summary>Patients pretreated , Her2-negative , advanced breast cancer receive chemotherapy capecitabine bendamustine maximum eight cycle afterwards capecitabine alone disease progression unacceptable toxic effect . Safety assessment conduct 3-weekly interval , efficacy assessment ( CT MRI ) conduct every 9 week . Aim study determine whether treatment capecitabine combination bendamustine efficacious safe .</brief_summary>
	<brief_title>Capecitabine + Bendamustine Women With Pretreated Locally Advanced Metastatic Her2-negative Breast Cancer</brief_title>
	<detailed_description>40 eligible patient enrol . A two-stage design efficacy safety bendamustine capecitabine evaluate follow recruitment first 20 patient . Upon favorable result 20 patient recruit reach target population 40 evaluable patient . Pretreatment eligible patient must include anthracyclines and/or taxanes .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Signed informed consent Female patient , age ≥ 18 year ( woman childbearing potential must negative pregnancy test screening must use effective contraception ) Advanced metastatic Her2negative breast cancer , histologically confirm At least one measurable lesion accord RECIST criterion ( Version 1.1 ) Documented disease progression Patients progression anthracycline and/or taxane treatment ( palliative adjuvant ) Life expectancy least 12 week Performance status 02 Hematologic : ANC ( absolute neutrophil count ) ≥ 1.5 x 109/L Hemoglobin ≥ 9 g/dL Platelets ≥ 100 x 109/L Liver Function : Albumin ≥ 2.5 g/dL Serum bilirubin ≤ 2 mg/dL AST ( Aspartate aminotransferase ) ALT ( Alanine aminotransferase ) ≤ 3 x ULN ( Upper limit Normal ) without liver metastasis 5 x ULN document liver metastasis Renal Function : Serum Creatinine ≤ 1.5 mg/dL OR Calculated Creatinine Clearance ≥ 40 mL/min Pregnant lactate woman Serious medical psychiatric disorder would interfere patient 's safety inform consent Radiation target lesion within last 4 week Active bacterial , viral fungal infection Patients clinically apparent brain metastasis Known Positivity HIV Positivity Hepatitis B C History malignancy ; patient diseasefree 5 year patient history completely resect nonmelanoma skin cancer successfully treat situ carcinoma eligible . Concurrent cancer therapy ( chemotherapy , immunotherapy , antihormonal biologic therapy ) concurrent treatment investigational drug Antihormonal therapy must discontinue prior start treatment ( possible least 3 week ) Known hypersensitivity study drug capecitabine bendamustine excipients Pretreatment capecitabine ( pretreatment infusional 5FU ( Fluorouracil ) adjuvant neoadjuvant setting allow ) bendamustine Treatment sorivudine derivates e.g . brivudin ( Mevir© ) within last 4 week study treatment capecitabine</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Bendamustine</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Pretreated</keyword>
	<keyword>Her2 negative</keyword>
	<keyword>Advanced breast cancer</keyword>
	<keyword>Metastatic breast cancer</keyword>
	<keyword>Anthracycline pretreatment</keyword>
	<keyword>Taxane pretreatment</keyword>
</DOC>